阳离子脂质体介导提高反义寡聚脱氧核苷酸转染卵巢癌细胞株SKOV3/mdr1的效率  

Inhibition of multiple drug resistance gene (MDR1) expression in ovarian carcinoma cell line SKOV3/mdrl by antisense oligodeoxynudeotide

作　　者：金滢[1] 潘凌亚[1] 张毅[2] 张双喜[2] 毛宁[2] 杨秀玉[1] 

机构地区：[1]中国医学科学院/中国协和医科大学北京协和医院妇产科,北京100730 [2]军事医学科学院基础医学研究所,北京100850

出　　处：《医学研究通讯》2001年第3期39-40,共2页Bulletin of Medical Research

摘　　要：多药耐药基因(MDR1)编码的P—糖蛋白(Pgp,P-170)是导致卵巢癌化疗失败的重要原因之一。本研究将针对MDR1基因的硫代反义寡聚脱氧核苷酸导入卵巢癌耐药细胞株SKOV3/mdr1,观察其对该细胞株P170表达的影响。反义寡聚脱氧核苷酸(MDR1-AS)通过阳离子脂质体介导或单纯转染的方式导入SKOV3/mdr1细胞,将正义寡聚脱氧核苷酸(MDR1-S)同样导入细胞为对照。经以脂质体介导的1.6μmol/L MDR1-AS转染后,Pgp阳性的细胞百分数从100％降至48.7％,经过16μmol/L和10μmol/L两个浓度的单纯MDR1-AS转染后,Pgp阳性细胞的百分数也从100％分别降至52.6％和86.7％。因此,通过阳离子脂质体介导可大大提高反义寡核苷酸转染的效率。One of the most important sources, which result in failure in ovary cancer treatment, is P- glycoprotein, which is coded by multidrug resistance gene ( mdrl) . To overcome the problem of multidrug resistance, the effectiveness of phosphrothioate antisense oligodeoxynucleotides (MDR1 - AS) in suppressing MDR1 gene expression in drug - resistance SKOV3/mdr1 cell line was investigated in this study MDR1 - AS was transfected into SKOV3/mdr1 cell mediated by lipofectamine or not with MDR1 - S treatment group as control.The percentage of Pgp+ cells was decreased from 100% to 48.7% by 1.6μmol/L MDR1 - AS plus lipofectamine treatment and from 100% to 52.6% or 86.7% by 16μmol/L or 10μmol/L MDR1 - AS treatment respectively.So the effect of transfection was significant elevated by plus lipofectamine.

关 键 词：反义寡核苷酸 卵巢癌 多药耐药 基因治疗 阳离子脂质体 

分 类 号：R737.31[医药卫生—肿瘤] R730.5[医药卫生—临床医学]